title: Climacteric Complaints after Breast Cancer - Is HRT an Option?
abstract: Systemic estrogen depletion is the mechanism of action of most endocrine treatment strategies, and a common side effect of most chemotherapy regimens that are currently used to treat invasive breast cancer. The ensuing immediate and profound decline in estrogen levels is, however, often associated with considerable climacteric complaints. While oral estrogen add-back therapy is effective in alleviating menopausal symptoms, it is feared that it might also promote tumor cell growth. This concern is largely based on circumstantial evidence from large trials in healthy women, in which hormone replacement therapy (HRT) resulted in a slight, albeit significant, increase in incident breast cancer. In breast cancer survivors, however, evidence from studies remains controversial. Despite these caveats, the severity of symptoms and the lack of effective alternatives still cause many women to opt for HRT. Nevertheless, HRT cannot generally be recommended as first-line therapy for climacteric complaints in women with a history of breast cancer. It may, however, be a valid option for selected women with climacteric symptoms refractory to previous non-hormonal treatments. In these cases, an individualized risk-benefit analysis is imperative before treatment initiation, and a treatment duration of less than 5 years with intermittent withdrawal attempts should be aimed for.
authors.affiliation: Division of Special Gynecology, Department of OB/GYN, Medical University of Vienna, Austria.
authors.forename: Christian F
authors.initials: CF
authors.lastname: Singer
references.citation: J Clin Oncol. 2001 Apr 15;19(8):2357-63
references.pmid: 11304788
references.citation: J Reprod Med. 2005 Mar;50(3):155-65
references.pmid: 15841927
references.citation: J Natl Cancer Inst. 1999 Dec 1;91(23):2020-8
references.pmid: 10580027
references.citation: Breast. 2007 Dec;16 Suppl 2:S182-9
references.pmid: 17983942
references.citation: JAMA. 2007 Apr 4;297(13):1465-77
references.pmid: 17405972
references.citation: Clin Cancer Res. 2007 Jul 15;13(14):4185-90
references.pmid: 17634547
references.citation: J Natl Cancer Inst. 2008 Apr 2;100(7):475-82
references.pmid: 18364505
references.citation: Ann Intern Med. 2005 May 17;142(10):855-60
references.pmid: 15897536
references.citation: Maturitas. 2004 Aug 30;48 Suppl 1:S4-6
references.pmid: 15337241
references.citation: Obstet Gynecol. 2008 Jan;111(1):77-87
references.pmid: 18165395
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3437-9
references.pmid: 17592152
references.citation: Clin Pharmacol Ther. 2008 Jan;83(1):160-6
references.pmid: 17882159
references.citation: J Natl Cancer Inst. 2005 Apr 6;97(7):533-5
references.pmid: 15812079
references.citation: Fertil Steril. 2004 Mar;81(3):617-23
references.pmid: 15037411
references.citation: Steroids. 2000 Oct-Nov;65(10-11):593-8
references.pmid: 11108864
references.citation: N Engl J Med. 2007 Apr 19;356(16):1670-4
references.pmid: 17442911
references.citation: Lancet. 2004 Feb 7;363(9407):453-5
references.pmid: 14962527
references.citation: Lancet Oncol. 2005 Sep;6(9):687-95
references.pmid: 16129369
references.citation: Lancet. 2003 Aug 9;362(9382):419-27
references.pmid: 12927427
references.citation: JAMA. 2002 Jul 17;288(3):321-33
references.pmid: 12117397
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1260-8
references.pmid: 18323549
references.citation: BJOG. 2002 Oct;109(10):1109-14
references.pmid: 12387462
references.citation: Menopause. 2007 May-Jun;14(3 Pt 1):518-27
references.pmid: 17224856
references.citation: Obstet Gynecol. 1998 Oct;92(4 Pt 1):580-4
references.pmid: 9764632
references.citation: J Clin Endocrinol Metab. 2002 Jan;87(1):16-23
references.pmid: 11788614
references.citation: Maturitas. 2002 Aug 30;42(4):255-8
references.pmid: 12191847
references.citation: J Clin Oncol. 2008 Feb 10;26(5):753-8
references.pmid: 18258983
references.citation: BJOG. 2005 Feb;112(2):228-33
references.pmid: 15663589